Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by 1900 Wealth Management LLC

1900 Wealth Management LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 2.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,263 shares of the medical research company’s stock after selling 31 shares during the quarter. 1900 Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $734,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in TMO. Oxler Private Wealth LLC increased its stake in Thermo Fisher Scientific by 31.2% in the first quarter. Oxler Private Wealth LLC now owns 9,939 shares of the medical research company’s stock valued at $5,776,000 after purchasing an additional 2,365 shares during the last quarter. Pegasus Partners Ltd. acquired a new position in Thermo Fisher Scientific in the first quarter valued at $207,000. Hartford Financial Management Inc. increased its stake in Thermo Fisher Scientific by 33.2% in the first quarter. Hartford Financial Management Inc. now owns 1,471 shares of the medical research company’s stock valued at $855,000 after purchasing an additional 367 shares during the last quarter. Dakota Wealth Management grew its position in Thermo Fisher Scientific by 50.2% during the first quarter. Dakota Wealth Management now owns 7,249 shares of the medical research company’s stock valued at $4,213,000 after acquiring an additional 2,424 shares during the period. Finally, Simplicity Wealth LLC grew its position in Thermo Fisher Scientific by 5,858.9% during the first quarter. Simplicity Wealth LLC now owns 26,219 shares of the medical research company’s stock valued at $15,239,000 after acquiring an additional 25,779 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders sold a total of 32,000 shares of company stock valued at $18,486,980 in the last three months. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $3.89 on Tuesday, reaching $590.12. 1,131,156 shares of the company were exchanged, compared to its average volume of 1,516,959. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company’s 50-day moving average is $576.49 and its two-hundred day moving average is $545.39. The firm has a market cap of $225.26 billion, a price-to-earnings ratio of 37.85, a P/E/G ratio of 2.47 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. The Goldman Sachs Group upped their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Citigroup initiated coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Finally, Barclays upped their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $607.35.

Read Our Latest Report on TMO

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Further Reading

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.